PT  - JOURNAL ARTICLE
ED  - ,
TI  - Management of corticosteroid-induced osteoporosis
AID  - 10.1136/dtb.2010.09.0047
DP  - 2010 Sep 01
TA  - Drug and Therapeutics Bulletin
PG  - 98--101
VI  - 48
IP  - 9
4099  - http://dtb.bmj.com/content/48/9/98.short
4100  - http://dtb.bmj.com/content/48/9/98.full
SO  - Drug Ther Bull2010 Sep 01; 48
AB  - Relevant BNF section: BNF 6.6 Treatment with corticosteroids can adversely affect bone metabolism. In particular, it lowers bone mineral density (BMD) and increases the likelihood of fragility fractures, the hallmarks of osteoporosis, hence the term ‘corticosteroid-induced osteoporosis’.1 Since corticosteroids are used for a wide variety of inflammatory conditions, corticosteroid-induced osteoporosis represents a substantial disease burden. Here we aim to provide advice on prophylaxis and treatment for osteoporosis in adults receiving corticosteroid therapy.